DCLK1 Overexpression and Knockdown in Pancreatic and Colorectal Cancer

DCLK1 isoform 1 or vector control was expressed in AsPC-1 cells utilizing lentivirus as previously described [21 (link)]. Overexpression was confirmed by Western blot. Knockdown of DCLK1 was achieved via transfecting SW480 cells with 50 nM of DCLK1-specific siRNA (Santa Cruz Biotechnology; SC-456178) or scrambled siRNA confirmed not to target any human genes for 72 h using Lipofectamine 3000 (Sigma). Efficient knockdown was confirmed by Western blot.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Weygant N., Ge Y., Qu D., Kaddis J.S., Berry W.L., May R., Chandrakesan P., Bannerman-Menson E., Vega K.J., Tomasek J.J., Bronze M.S., An G, & Houchen C.W. (2016). Survival of patients with gastrointestinal cancers can be predicted by a surrogate microRNA signature for cancer stem-like cells marked by DCLK1 kinase. Cancer research, 76(14), 4090-4099.

Publication 2016

Lipofectamine 3000

Cells Dclk1 Isoform Lentivirus Lipofectamine Sirna Western blot

Corresponding Organization : Coare Biotechnology (United States)

Other organizations : City Of Hope National Medical Center

Top 5 similar protocols

Variable analysis

independent variables

DCLK1 isoform 1 overexpression
DCLK1 knockdown

dependent variables

Cell phenotype (not explicitly mentioned)

control variables

Vector control
Scrambled siRNA

controls

Positive control: Vector control
Negative control: Scrambled siRNA

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!